行情

GLYC

GLYC

GlycoMimetics
NASDAQ

实时行情|Nasdaq Last Sale

2.110
+0.030
+1.44%
已收盘, 16:00 04/03 EDT
开盘
2.070
昨收
2.080
最高
2.180
最低
1.940
成交量
43.62万
成交额
--
52周最高
13.44
52周最低
1.820
市值
9,196.01万
市盈率(TTM)
-1.5764
分时
5日
1月
3月
1年
5年

分析师评级

6位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测GLYC价格均价为8.80,最高价位16.00,最低价为4.000。

EPS

GLYC 新闻

更多
  • 为美元续命,美联储干了这件大事!
  • 新浪财经-自媒体综合 · 1小时前
  • 债务危机幽灵再现,激进放水后美联储或只剩一个策略
  • 新浪财经综合 · 1小时前
  • 德国今年经济或因疫情萎缩3-6%
  • 新浪财经 · 2小时前
  • 亚太股市因疫情放缓希望而大涨,多个股指进入技术性牛市
  • 环球外汇网 · 2小时前

所属板块

生物技术和医学研究
-0.50%
制药与医学研究
-0.22%

热门股票

代码
价格
涨跌幅

GLYC 简况

GlycoMimetics, Inc. is a clinical-stage biotechnology company. The Company focuses on the discovery and development of glycomimetic drugs. The Company operates through the identification and development of glycomimetic compounds segment. The Company is developing its lead drug candidate, GMI-1070 (Rivipansel), for the treatment of vaso-occlusive crisis (VOC), a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease. The Company is developing GMI-1271, a specific E-selectin inhibitor, to be used in combination with chemotherapy to treat patients with acute myeloid leukemia (AML), multiple myeloma (MM) and other hematologic cancers. The Company has an additional drug candidate, GMI-1359, that targets both E-selectin and a chemokine receptor, CXCR4. The Company is also advancing other preclinical-stage programs, which include small-molecule glycomimetic compounds that inhibit the proteins galectin-3 and galectin-9.
展开

微牛提供GlycoMimetics Inc(NASDAQ-GLYC)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的GLYC股票新闻,以帮助您做出投资决策。